1. Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells.
- Author
-
Li, Chao, Liu, Zhong, Anderson, Justin, Liu, Zhongyu, Tang, Liping, Li, Yao, Peng, Ning, Chen, Jianguo, Liu, Xueming, Fu, Lianwu, Townes, Tim M., Rowe, Steven M., Bedwell, David M., Guimbellot, Jennifer, and Zhao, Rui
- Subjects
EPITHELIAL cells ,CYSTIC fibrosis transmembrane conductance regulator ,NONSENSE mutation ,GENETIC mutation ,CYSTIC fibrosis - Abstract
A major unmet need in the cystic fibrosis (CF) therapeutic landscape is the lack of effective treatments for nonsense CFTR mutations, which affect approximately 10% of CF patients. Correction of nonsense CFTR mutations via genomic editing represents a promising therapeutic approach. In this study, we tested whether prime editing, a novel CRISPR-based genomic editing method, can be a potential therapeutic modality to correct nonsense CFTR mutations. We generated iPSCs from a CF patient homozygous for the CFTR W1282X mutation. We demonstrated that prime editing corrected one mutant allele in iPSCs, which effectively restored CFTR function in iPSC-derived airway epithelial cells and organoids. We further demonstrated that prime editing may directly repair mutations in iPSC-derived airway epithelial cells when the prime editing machinery is efficiently delivered by helper-dependent adenovirus (HDAd). Together, our data demonstrated that prime editing may potentially be applied to correct CFTR mutations such as W1282X. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF